Literature DB >> 17607339

Aripiprazole as the causative agent of neuroleptic malignant syndrome: a case report.

Daniel Molina, Leslie E Tingle, Xiaohui Lu.   

Abstract

Entities:  

Year:  2007        PMID: 17607339      PMCID: PMC1896300          DOI: 10.4088/pcc.v09n0211b

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


× No keyword cloud information.
  17 in total

1.  SERUM CREATINE PHOSPHOKINASE (CPK) ACTIVITY IN DISORDERS OF HEART AND SKELETAL MUSCLE.

Authors:  J W HESS; R P MACDONALD; R J FREDERICK; R N JONES; J NEELY; D GROSS
Journal:  Ann Intern Med       Date:  1964-12       Impact factor: 25.391

2.  Aripiprazole and atypical neuroleptic malignant syndrome.

Authors:  Scott Spalding; Norman E Alessi; Karam Radwan
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2004-12       Impact factor: 8.829

Review 3.  Modern antipsychotic drugs: a critical overview.

Authors:  David M Gardner; Ross J Baldessarini; Paul Waraich
Journal:  CMAJ       Date:  2005-06-21       Impact factor: 8.262

4.  Practice patterns and potential solutions to the shortage of providers of older adult mental health services.

Authors:  Nancy P Hanrahan; Eileen M Sullivan-Marx
Journal:  Policy Polit Nurs Pract       Date:  2005-08

Review 5.  Neuroleptic malignant syndrome.

Authors:  J L Levenson
Journal:  Am J Psychiatry       Date:  1985-10       Impact factor: 18.112

6.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

7.  Neuroleptic malignant syndrome: review of experience with children and adolescents.

Authors:  R Steingard; A Khan; A Gonzalez; D B Herzog
Journal:  J Child Adolesc Psychopharmacol       Date:  1992       Impact factor: 2.576

Review 8.  Aripiprazole: efficacy and tolerability profile of a novel-acting atypical antipsychotic.

Authors:  Peter F Buckley
Journal:  Drugs Today (Barc)       Date:  2003-02       Impact factor: 2.245

Review 9.  Olanzapine induced neuroleptic malignant syndrome--a case review.

Authors:  Ales Kogoj; Ingrid Velikonja
Journal:  Hum Psychopharmacol       Date:  2003-06       Impact factor: 1.672

Review 10.  Neuroleptic malignant syndrome. Recognition, prevention and management.

Authors:  V R Velamoor
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

View more
  2 in total

1.  Neuroleptic malignant syndrome associated with haloperidol use in critical care setting: should haloperidol still be considered the drug of choice for the management of delirium in the critical care setting?

Authors:  Deepali Dixit; Pranabh Shrestha; Marc Adelman
Journal:  BMJ Case Rep       Date:  2013-07-12

Review 2.  Neuroleptic malignant syndrome associated with atypical antipsychotic drugs.

Authors:  Julian N Trollor; Xiaohua Chen; Perminder S Sachdev
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.